



type 1 diabetes



annual report 2010-11

contents

Mission	1
Highlights	2 – 3
Type 1 diabetes facts	4
About JDRF	5
Chairman's message	6
CEO's message	7
Driving Research Progress	8
Cure, Treat, Prevent	9
Research achievements – beta cells	10
Research achievements – immune	11
Research achievements – complications	12
Research achievements – glucose control	13
Clinical Research Network	14
My Story – Prof Tim Jones	15
Research program list	16 – 17
Influencing Decision Makers	18
Conversations with government	19
Policy achievements	20
My Story – The Hon Mark Dreyfus QC MP	21
Connecting Communities	22
Connecting the T1D community	23
Sharing the hope for a cure	24
My Story – Kerrie McCallum	25
Plugging into best practice	26
Recognising excellence in care	27
Funding the Future	28
Walk, Ride, Spin	29
Jelly babies, special events	30
Team Cure Diabetes	31
My Story – Roy Laidlaw	32
Partnering with business	33
Pro bono and volunteers	34
The generosity of individuals	35
Thank you to supporters	36 – 37
My Story – Kristen Mason	38
Linking into Expertise	39
Corporate governance	40
Board of Directors	41 – 42
Advisory Board	43
Advisory Panels	44
JDRF Leadership Team	45
Financial information	46 – 48
Directory of JDRF offices	49



mission

**To find a cure for type 1 diabetes
and its complications through the
support of research.**

highlights of 2010/11



Driving research progress

- Internationally, JDRF invested more than \$116 million into type 1 diabetes research, including support for 62 Australian programs.
- Research progressed significantly over the year and we now have several new treatments moving into clinical trials as well as a better understanding of disease processes.
- Eighteen Australians have received islet transplants through the Australian Islet Transplantation Program.
- JDRF launched the Australian Type 1 Diabetes Clinical Research Network to encourage and support local clinical trials.

Influencing decision makers

- Over 500 volunteer advocates, ranging in age from 4 to 66 years, met regularly with local politicians to keep them in touch with the type 1 diabetes community.
- JDRF was involved with important policy improvements including increased access to the Carers Allowance and a better NDSS.

Connecting communities

- JDRF reached out to the community by distributing 2200 information kits, expanding the JDRF Peer Support Program and rewarding outstanding diabetes care with the first-ever Diabetes Educator Awards.
- 118 subsidised insulin pumps were delivered to children around the country through the Insulin Pump Program.
- 34,000 people were connected to JDRF through our online newsletter and blog 'Path to a Cure'.

Funding the future

- Together with our supporters we raised \$9.9 million.
- Over 20,000 people were part of the Walk, Ride and Spin to Cure Diabetes.
- Team Cure Diabetes was launched to help adventurous supporters contribute in their own way.
- Many in our community made generous donations, bequests and pledges towards our goal.



Type 1 diabetes is a lifelong autoimmune disease that destroys the body's ability to produce insulin, a hormone vital for life. It is generally diagnosed in young people but can strike at any age. It can be passed through families or arise unexpectedly.

CAUSES – are not fully understood, but scientists believe that a person's genes play a role along with a variety of potential environmental factors.

TREATMENT – involves a constant infusion or multiple daily injections of insulin, along with a strictly regulated lifestyle, just to stay alive.

COMPLICATIONS – can include coma, blindness, kidney failure, stroke and amputation.

A CURE – will be found. By working together we will develop new treatments, discover new ways of preventing disease onset and ultimately eradicate type 1 diabetes.



**6 new cases of type 1
diabetes are diagnosed in
Australia every day**

JDRF is dedicated to a better life for kids and adults with type 1 diabetes and ultimately, a cure. A future free of this disease is the vision that has united thousands of Australians since 1982.

JDRF is passionate about turning brilliant scientific ideas into tangible health improvements as quickly as possible.

Globally, JDRF has funded the very best research into type 1 diabetes, giving kids and adults with type 1 diabetes a healthier life today and bringing us closer than ever to a cure.

JDRF doesn't just support researchers at lab benches. Through our local and international networks we also steer the scientific agenda according to the needs of the type 1 community and facilitate the translation of promising research into real medical solutions through clinical trials and industry partnerships.

The type 1 diabetes community supports and inspires us, helping us to deliver improvements to the lives of people with type 1 diabetes now and for the future.



Chairman's message

Positive and fruitful relationships are the foundation of all JDRF activities – relationships with scientists, decision makers, business and, most importantly, with members of the type 1 diabetes community.

JDRF's associations are not purely built around the give and take of funds. We focus on developing productive partnerships and support networks that all work towards a clear goal – curing, treating and preventing type 1 diabetes and its complications.

I know from personal experience that type 1 diabetes doesn't just affect an individual. It has an impact across family, friends and communities, and even further to researchers, government, clinicians and business partners. This report profiles how these groups are working together to help make progress towards our ultimate goal.

Over the past year, JDRF has called upon the expertise of all of our partners to undertake a strategic review of research focus and activity. After input from all sectors, JDRF has recognised the need for developing treatments to alleviate the disease burden of today, while also accelerating the vital work towards preventing and curing the disease in the future. You can read more about how JDRF aims to achieve these goals in this report.

Defining JDRF's global directions is essential for future research success, but it's the tireless day-to-day work of our local supporters that keep the wheels turning on the road to a cure.

Thanks must go to the JDRF Board of Directors, Advisory Board and Advisory Panels for sharing their knowledge and networks. JDRF state-based committees and Chapters bring expertise and passion that ensures local success. Individual and corporate supporters enthusiastically attend JDRF fundraising events and, in the case of Team Cure Diabetes, organise their own. Volunteers sell jelly baby merchandise, staff information stalls, speak at functions and meet with politicians. And, of course, we mustn't forget the researchers and health professionals working to make a real difference to the lives of people with type 1 diabetes.

To all of these dedicated people, we say thank you.

A handwritten signature in dark ink, appearing to read 'Steve Higgs'.

Steve Higgs, Chairman

CEO's message

JDRF is working on behalf of everyone, at any age, living with type 1 diabetes. Our research is relevant to the newly diagnosed, those who have lived with the disease for many years and those at risk of developing it in the future.



Research into type 1 diabetes has accelerated rapidly. We now have a good understanding of who's at risk of developing it and how it progresses. We're creating and testing novel immune therapies and cell replacement or regeneration techniques that will ultimately provide a cure. We are testing technology to make life easier and safer for people living with the condition, reducing the health burdens of today as well as the risk of complications tomorrow.

There are challenges that remain, in particular the commercial, regulatory and reimbursement obstacles that must be overcome before research can be translated to clinical care and made available to those that will benefit from it. JDRF has taken on the responsibility of navigating these obstacles and removing any barriers preventing the delivery of promising new therapies and technologies.

JDRF Australia made an exciting step this year towards addressing one of these barriers with the launch of the Australian Type 1 Diabetes Clinical Research Network (CRN). The CRN will accelerate the translation of good research ideas into therapies tested in people, and increase patient access to new treatments by supporting clinical trials – both the development of local trials and the expansion of international trials to Australia. In partnership with the research community and supported by the Department of Health and Ageing, the CRN has already announced funding for four trials nationally.

As a not-for-profit organisation, JDRF relies upon the ongoing generosity of the community. This year, the combined activities of JDRF

and our supporters raised over \$9.9 million for the best Australian research into type 1 diabetes.

JDRF fundraising programs – the Walk, Ride and Spin to Cure Diabetes – motivated thousands of people from around Australia to join together and raise funds. The annual JDRF Jelly Baby Month was also a success, generating over \$800,000. Our new community fundraising program “Team Cure Diabetes” prompted supporters to coordinate their own events, with results ranging from an elegant art display to a thrill-seeking parachute jump.

In 2010/11, we focused on better engagement with the type 1 diabetes community, expanding our successful Peer Support Program and distributing support kits to the newly diagnosed. We also recognised and rewarded excellence in diabetes care with the inaugural Diabetes Educator Awards.

Successful interactions with all levels of government resulted in a number of positive policy changes, improving the lives of people and families living with type 1 diabetes as well as laying the foundations for future activities.

We know that the search for a cure for type 1 diabetes is a challenging one, but with the continued support of our partners and the type 1 diabetes community, we will be successful.

A handwritten signature in dark ink, appearing to read 'Mike Wilson'.

Mike Wilson, Chief Executive Officer



driving research progress

In 2010/11, JDRF invested more than \$116 million globally into type 1 diabetes research. This included support for 62 Australian research projects.


Working in close collaboration with clinicians, researchers and the type 1 diabetes community, JDRF has defined the following therapeutic research areas that can have the most benefit to people with type 1 diabetes.

- 1) Cure Therapeutics** - beta cell and immune therapies that prevent, stop and reverse the disease progression.
- 2) Treatment Therapeutics** - addressing the long and short-term health challenges involved with type 1 diabetes.

By supporting these key areas, JDRF will increase impact, reduce duplication and speed up translation of basic research into new therapies for people at all stages – from preventing onset of the disease to those at risk, to the newly diagnosed and those who have lived with the condition for many years.

JDRF research is focused on improving the lives of people with diabetes today and in the future. Whilst the ultimate aim is to cure type 1 diabetes, JDRF recognises the need to keep people with type 1 diabetes healthy enough to fully benefit from the cure when it is found, as well as achieving the goal of preventing the disease in future generations.

This means JDRF is working towards a solution for everyone with type 1 diabetes and also those who may be at risk.



Beta Cell Therapies

Research in this area is focused on identifying ways to either trigger the body to grow insulin-producing cells, or directly replacing them using cells from outside the body.

JDRF is funding a wide spectrum of research activities in this exciting area from identifying the building blocks of pancreas development to creating better surgical techniques for cellular transplantation.

Research progress

- Australian Islet Transplantation Program clinicians have now transplanted 18 people. JDRF and research leaders are working towards making this program more widely available through the national health system.
- JDRF researchers identified an enzyme that triggers new beta cell production in mice, a breakthrough that may help researchers stimulate the same process in humans.
- A new clinical trial called REPAIR T1D launched to test a promising combination therapy of two existing drugs, Sitagliptin and Lansoprazole, shown to regenerate insulin-producing cells in mice.
- A second stage clinical trial is investigating a new regeneration therapy called Exsulin. Initial studies showed Exsulin triggers stem-like cells to differentiate into insulin-producing cells.
- JDRF-funded research has shown that over two thirds of Joslin Medallists – people surviving fifty years of type 1 diabetes – retain some beta cell function reinforcing that beta cells can be stimulated to regenerate, even in people with long term disease.

The future

A number of successful outcomes in this research area have shown beta cells can be regenerated, even in people with long-term type 1 diabetes. Replacement of beta cells, whether donated or grown in a lab, is becoming a reality and clinical trials are underway to assess safety and effectiveness.

Immune Therapies

Immune therapies aim to prevent, stop and reverse the autoimmune process that kills off insulin-producing beta cells by addressing the immune system as well as the genetic and environmental basis of type 1 diabetes.

This research targets people at all stages of type 1 diabetes; preventing the onset of the disease, delaying the need to take insulin in the newly diagnosed, and stopping the disease returning in people undergoing beta cell therapy to replace insulin production.

Research progress

- Australian JDRF research has shown that changes in the RAGE receptor gene are linked to type 1 diabetes. Restoring RAGE levels in mice predisposed to type 1 diabetes decreased disease incidence, showing it is a powerful target for prevention therapies.
- The molecules IL-21 and IL-17 were newly identified by Australian researchers as important components of the immune attack causing type 1, creating new targets for disease prevention.
- A preliminary trial by the JDRF funded TrialNet Consortium has shown a therapy called Abatacept successfully blocks part of the immune attack on beta cells, delaying insulin treatment in newly diagnosed people by up to nine months.
- JDRF researchers prevented type 1 diabetes in mice by attracting “protective” immune cells to the pancreas. This promising research provides a new platform for prevention.
- Two studies investigating the links between type 1 diabetes and viral infection, have shown a strong association between enterovirus infection and the development of type 1 diabetes.

The future

Researchers now have an intricate understanding of the type 1 diabetes immune system and are scrutinising the process to identify target areas for treatment. Excitingly, suitable drug therapies are already in existence and being trialled. Research into the genetic and environmental triggers of type 1 diabetes enable researchers to accurately identify the type 1 diabetes risk, allowing timely action to prevent onset.

Complications Therapies

This research pathway aims to prevent onset, cease progression and reverse the effects of diabetes complications, improving overall health and wellbeing and reducing associated personal and economic burdens.

Recent research breakthroughs by JDRF scientists have changed our understanding of how and why diabetes complications occur. Further advances generated by JDRF research, in particular earlier diagnosis and improved treatment, have already had a significant effect on the overall health of people with type 1 diabetes.

Research progress

- Two international studies involving Australian researchers have identified important predictors of complications in people with type 1 diabetes. High levels of two separate biomarkers, called sRAGE and serum adiponectin, resulted in a greater risk of cardiovascular disease and shortened life span.
- Final stage clinical trials funded by JDRF and Genentech have shown that the drug Lucentis stabilises and reverses the symptoms of diabetic macular edema. The product has now been approved for clinical use in Europe.
- The JDRF Joslin Medallists Study showed that a high proportion of this group were free of serious diabetes complications, regardless of their glycemic control. This suggests the presence of protective factors that can potentially be identified and developed into new therapies.

The future

Successful JDRF research has already resulted in better diagnosis of diabetes complications meaning earlier treatment and better outcomes. Recent research is diagnosing complications even earlier, and even pinpointing people at risk of certain conditions as soon as they are diagnosed. Ultimately this will result in more effective and more individual ways to manage health complications.

Glucose Control Therapies

Maintaining the short and long term control of blood sugars is vital to improving the chances of ongoing good health.

Researchers in this area are focused on restoring optimal blood glucose control for people at all stages of type 1 diabetes. This includes the development of the artificial pancreas – a closed loop system that continually monitors blood glucose levels and automatically responds with an appropriate dose of insulin – as well as improvements in insulin delivery, glucose monitoring and day-to-day diabetes management regimens.

Research progress

- Clinical trials have begun in Western Australia looking at the use of the artificial pancreas in children with type 1 diabetes.
- Australian researchers investigating Dose Adjustment for Normal Eating (DAFNE), a program that educates patients on how to better calculate insulin required for diet, have shown that complying with the program guidelines significantly improved wellbeing and reduced diabetes-related distress.
- JDRF has launched a research program to speed the development of faster-acting insulin and insulin delivery systems. The goal is to use fast forms of insulin in the artificial pancreas to more closely mimic the action of the human pancreas.
- Two new trials using an overnight closed-loop artificial pancreas have shown an overall improvement in glycemic control and an increase in time spent in target glucose levels.

The future

Research in this area is focused purely on improving the lives of people living with type 1 diabetes and significant progress has already been made. The next big step is taking trials of the first artificial pancreas prototypes out of hospital settings and into homes. Concurrent with this, researchers will also be testing new forms of insulin and new management techniques for minimising blood sugar fluctuations to ensure good health is maintained while a fully functioning artificial pancreas system is developed.

Type 1 Diabetes Clinical Research Network

JDRF uses its resources to find and fill gaps in the research pipeline to ensure that potential treatment and eventually a cure are delivered to patients as quickly as possible. One such gap is the translation of laboratory research into clinical trials - the final stages of research before a new treatment is approved for wider use.

In response to this, JDRF Australia has launched the Australian Type 1 Diabetes Clinical Research Network (CRN). This collaboration between researchers, institutions, patients, industry and international networks is supported by funding from the Australian Government and a personal pledge by JDRF President, Dr Susan Alberti AO.

The Clinical Research Network will -

- **Increase patient access to the latest type 1 diabetes treatments and trials**
- **Improve interaction between patients, clinicians and trial sponsors**
- **Build on existing expertise to attract more clinical trials to Australia**

Complementing the CRN is the JDRF focus on partnering with key commercial and government groups both locally and internationally. This enables us to speed up final testing and overcome the financial and regulatory obstacles involved with moving a new therapy to market.

JDRF currently supports more than 40 trials in Australia and around the world. Four new trials in Western Australia, New South Wales and Victoria have been selected for CRN support.



**Professor Tim Jones -
Paediatric endocrinologist and JDRF-funded researcher
Princess Margaret Hospital, University of Western
Australia**

I've cared for young people with type 1 diabetes for over two decades. Improvements in disease management during that time have been extraordinary, but there is still a lot of work to do. Of particular importance is the translation of exciting laboratory research into new and widely available treatments. This can only be done using human clinical trials.

My research team has recently been granted funding through the JDRF Clinical Research Network to test the first stage of a closed loop artificial pancreas system in 200 young people around Australia. Using a newly developed insulin pump and sensor system, participants will hopefully be able to prevent low blood glucose and hypoglycemia without needing constant human intervention.

Our trial will act as a stepping stone for the next one until we have enough information to gain government approval for widespread use. Trials don't stop once the treatment is available to patients - researchers will continue to improve and evolve the system until a complete solution is found.

With the exceptional depth of both clinical and laboratory-based scientific knowledge in Australia, there is a huge potential for type 1 diabetes clinical research. The JDRF Clinical Research Network will provide the ongoing infrastructure, support and encouragement that researchers need to take the step from the lab to the clinic – and ultimately to better health outcomes for people with type 1 diabetes.

Research Programs

JDRF Grants

Australia III: DVDC	National Health and Medical Research Council of Australia		Australia III - DVDC (Diabetes Vaccine Development Centre)
Australia IV	National Health and Medical Research Council of Australia		Australia IV
Dr Tom Brodnicki	St Vincent's Institute of Medical Research	VIC	How does bacterial infection affect susceptibility to type 1 diabetes?
Dr Mark Chong	Walter & Eliza Hall Institute of Medical Research	VIC	The microRNAome of CD4+ T cells as a potential biomarker for autoreactivity
Dr Mark Chong	Walter & Eliza Hall Institute of Medical Research	VIC	The microRNA transcriptome of thymic antigen presenting cells
Prof Mark Cooper	Baker IDI Heart and Diabetes Institute	VIC	Set 7: a novel target for diabetic vascular complications
Prof Mark Cooper	Baker IDI Heart and Diabetes Institute	VIC	Targeting CDA1 to treat diabetic renal fibrosis
A/Prof Barbara Coulson	University of Melbourne	VIC	Rotavirus modulation of type 1 diabetes
Prof Nathan Efron	Queensland University of Technology	QLD	A longitudinal study of ophthalmic markers of neuropathy in Type 1 diabetes
A/Prof Assam El-Osta	Baker IDI Heart and Diabetes Institute	VIC	Role of epigenetic persistence in diabetic vascular complications
A/Prof Assam El-Osta	Baker IDI Heart and Diabetes Institute	VIC	Suppression and reversal of diabetic complications mediated by hyperglycemia using epigenetic inhibitors
A/Prof Assam El-Osta	Baker IDI Heart and Diabetes Institute	VIC	FinDiane Epigenome of Type 1 Diabetes (Epitype1) Studies
A/Prof Josephine Forbes	Baker IDI Heart and Diabetes Institute	VIC	Synergistic methods for mitochondrial rescue in diabetic nephropathy
A/Prof Josephine Forbes	Baker IDI Heart and Diabetes Institute	VIC	RAGE as a link between environmental and genetic susceptibility to type 1 diabetes
Prof Leonard Harrison	Walter & Eliza Hall Institute of Medical Research	VIC	JDRF International Clinical Sites – TrialNet
Prof Leonard Harrison	Walter & Eliza Hall Institute of Medical Research	VIC	Evidence for increased numbers of stem cells in human T1D pancreas
Dr Mugdha Joglekar	St Vincent's Institute of Medical Research	VIC	Inhibition of cytotoxic T lymphocyte-mediated beta cell killing
Dr Jan Kranich	Garvan Institute of Medical Research	NSW	Gut bacteria, short-chain fatty acids and Gpr43 in type-1 diabetes
Dr Balasubramanian Krishnamurthy	St Vincent's Institute of Medical Research	VIC	The role of proinsulin specific T cells after the onset of autoimmunity
Dr Trang Ly	University of Western Australia	WA	Low Glucose Suspend Study
Dr Stuart Mannering	St Vincent's Institute of Medical Research	VIC	Analysis of human islet-infiltrating T cells in type 1 diabetes
Dr Stuart Mannering	St Vincent's Institute of Medical Research	VIC	A preclinical model for human insulin specific CD4+ T-cell responses
Dr Brad Marsh	University of Queensland	QLD	3D Structural Characterisation of Human Islet Dysfunction/Destruction
Dr Antonia Miller	Monash University	VIC	The contribution of the (pro)renin receptor to diabetic retinopathy
Dr Charmaine Simeonovic	Australian National University	ACT	Heparan sulfate levels mark the health status of human islet beta cells
Prof Jonathan Sprent	Garvan Institute of Medical Research	NSW	Treg expansion for islet allotransplantation
Dr Martin Stebbing	Royal Melbourne Institute of Technology	VIC	Role of microglia in diabetic complications and autonomic neuropathy
Dr Raymond Steptoe	University of Queensland	QLD	Induction of tolerance in memory diabetogenic T cells
Dr Sih Min Tan	Baker IDI Heart and Diabetes Institute	VIC	The effects of novel GPx1-mimetics in diabetic nephropathy
Prof Ranjeny Thomas	University of Queensland	QLD	Pathological changes associated with chronic RelB activation in T1D
Prof Ranjeny Thomas	University of Queensland	QLD	RelB response as a biomarker of diabetes susceptibility
Dr Chris Tikellis	Baker IDI Heart and Diabetes Institute	VIC	ACE2 in the vascular complications of type 1 diabetes

Research Programs

JDRF Grants

Dr Yuxia Zhang	Walter & Eliza Hall Institute of Medical Research	VIC	Engineering antigen specific regulatory T cells
Dr Yuxing Zhao	St Vincent's Institute of Medical Research	VIC	Autoimmune destruction of beta cells in type 1 diabetes

Clinical Research Network

A/Prof Maria Craig	Childrens Hospital at Westmead	NSW	The Australasian Paediatric Endocrine Group Clinical Trials Network
A/Prof Alicia Jenkins	University of Melbourne	VIC	Improving health outcomes in type 1 diabetes - REMOVAL substudy
Prof Timothy Jones	University of Western Australia	WA	Low Glucose Suspend Study
Prof Timothy Jones	University of Western Australia	WA	Adolescent diabetes intervention trial: Australia (AddIT)

ITP Grants

Prof Peter Cowan	St Vincent's Hospital	VIC	Protecting islet allografts from innate and cognate immunity
Dr Karen Dwyer	University of Melbourne	VIC	CD39 Expression prevents auto-immune destruction of beta cells
Prof Christopher Goodnow	Australian National University	ACT	Antibody enhanced antigen presentation for CD4 cell tolerance of islets
Dr Kate Graham	St Vincent's Institute of Medical Research	VIC	Protecting islets from allo-and autoimmune CTLs by overexpressing SOCS1
A/Prof Shane Grey	Garvan Institute of Medical Research	NSW	Generating Islet Graft Tolerance by Targeting Apoptosis and NF-kappaB Activation
Dr Jenny Gunton	Garvan Institute of Medical Research	NSW	Increasing HIF1a improves Islet Transplant Outcome
Prof Bruce Hall	University of NSW	NSW	Induction of tolerance to islet allografts by anti-CD3 and CD4+ CD25+ cells
Prof Leonard Harrison	Walter & Eliza Hall Institute of Medical Research	VIC	Adult human pancreas stem progenitor cells
A/Prof Gerard Hoyne	University of Notre Dame	WA	Genes that regulate tolerance and beta cell survival in type 1 diabetes
A/Prof Fang-Xu Jiang	University of Western Australia	WA	Investigating mechanisms of beta-cell differentiation from islet progenitor
Prof Tom Kay	St Vincent's Institute of Medical Research	VIC	The Tom Mandel Australian Islet Transplant Program
Dr Ross Laybutt	Garvan Institute of Medical Research	NSW	Cytokine-induced ER stress leads to beta-cell dedifferentiation
A/Prof Andrew Lew	Walter & Eliza Hall Institute of Medical Research	VIC	Targeting dendritic cells for local immunosuppression and tolerance
A/Prof Andrew Lew	Walter & Eliza Hall Institute of Medical Research	VIC	Selective suicide of cross-presenting dendritic cells to stop rejection
Dr Stuart Mannering	St Vincent's Institute of Medical Research	VIC	Human T-cell responses to islet- and allo-antigens after islet transplant
Dr Zia Mollah	St Vincent's Institute of Medical Research	VIC	Inhibition of the perforin/granzyme pathway in islet allograft rejection
A/Prof Mark Nottle	University of Adelaide	SA	Use of ES cells to advance xeno-islet transplantation
Dr Bronwyn O'Brian	University of Technology	NSW	Parasite immunomodulatory molecules prevent rejection of islet transplants
Prof Philip O'Connell	Westmead Hospital	NSW	National Pancreas Transplant Unit, Westmead Hospital
Prof Graeme Russ	Queen Elizabeth Hospital	SA	The South Australian & Northern Territory Islet Program

NHMRC Partnership Grants

Prof Anthony d'Apice	St Vincent's Health	VIC	Which transgenic pig will be used for islet transplantation in humans?
A/Prof Shane Grey	Garvan Institute of Medical Research	NSW	Beta cell mass and function in type 1 diabetes and islet transplantation
Prof Ed Stanley	Monash University	VIC	Derivation of pancreatic beta cells from embryonic stem cells
Prof Joseph Trapani	University of Melbourne	VIC	Cell death pathways and type 1 diabetes



influencing decision makers

JDRF works with all levels of government to help deliver shared goals including improvements to the health and wellbeing of people with type 1 diabetes and support for research and clinical programs.

JDRF has opened up thousands of conversations between the type 1 diabetes community and decision makers at every level of government across Australia, with remarkable results.

The goal is to increase government awareness of type 1 diabetes, to secure ongoing funding for access to better treatments and to generate additional support for medical research to find a cure.

Conversations with government

JDRF invites the type 1 diabetes community to participate in an ongoing conversation with government through the JDRF Advocates Program.

Over 500 advocates, ranging from 4 years to 66 years of age, are now working tirelessly to keep type 1 diabetes in the forefront of political minds. In 2010/11, advocates across the country visited and sent regular letters to their state and federal politicians, featured in electorate newsletters and websites, and even sent the Prime Minister, Leader of the Opposition and Minister for Health and Ageing personalised JDRF Christmas Cards.

Working with decision makers

JDRF is in regular contact with all levels of government and have significant input into the development and evaluation of type 1 diabetes programs across the areas of research, clinical management and financial support. Securing continued access to the best disease management and treatment such as the Insulin Pump Program and the Islet Transplantation Program was a particular focus of the last year.

A major event in 2010/11 was the launch of the Australian Clinical Research Network (CRN) at Parliament House, Canberra. Launched by the Hon Mark Dreyfus QC MP and CRN Chairman the Hon Dr Michael Wooldridge, this event generated significant interest across both houses of Parliament.

Parliamentary Diabetes Support Group (PDSG)

The PDSG is a Federal bipartisan support group established to ensure that diabetes and diabetes research remains a national health priority.

This year, JDRF worked with the PDSG across a number of areas including the Insulin Pump Program, the Carers Allowance review and improving the NDSS.

JDRF was well represented at the 10th Anniversary PDSG Dinner in 2011 with JDRF CEO Mike Wilson presenting PDSG member Senator Guy Barnett with a Golden Walk Boot to recognise his commitment and advocacy for people with type 1 diabetes.

Policy and Advocacy

JDRF champions the needs of the type 1 diabetes community at all levels of government. Our evidence based approach to advocacy has positioned us as a reliable and reputable information source while ensuring the best possible health, economic and social outcomes for all Australians with type 1 diabetes.

In 2010/11, JDRF contributed to a number of policy based activities including -

- **Protecting access to the Carers Allowance**

Together with the type 1 community and the Australian Diabetes Council, JDRF lobbied the office of the Minister for Families and Community Services to conduct an official review of the Carers Allowance and its access restrictions for type 1 families. JDRF and the Australian Diabetes Council made a strong joint submission to that review, including engaging families negatively affected by the pre-existing policy

- **Refining the National Diabetes Services Scheme (NDSS)**

The Department of Health and Ageing approached JDRF for input into a paper investigating the current arrangements for the NDSS. In the response, JDRF highlighted various priority areas and indicated potential areas for increased support and access.

- **Improving access to diabetes specialists**

JDRF provided positive feedback to the Department of Health and Ageing in response to the white paper 'Connecting Health Services with the Future: Modernising Medicare by providing Rebates for Online Consultations'. Online consultations with a doctor are now an official item that can be claimed under Medicare as part of the Telehealth initiative - a move that has the potential to make life easier for both clinicians and the type 1 community, particularly those who live in rural and remote areas.





The Hon Mark Dreyfus QC MP

Federal Member for Isaacs and Parliamentary Secretary for Cabinet

I met Billie Angelone for the first time in 2008, when she was 7 years of age. Billie and her mum, Nicky, visited me to talk about Billie's role as a Youth Ambassador for JDRF and their experience as a family living with diabetes. You cannot meet Billie without leaving amazed by her resilience, maturity and confidence. At the age of 4 she was diagnosed with type 1 diabetes. By the time I met her, she had endured thousands of finger-pricks and needles. Rather than complain, Billie and her family looked to the future and decided what they needed to do to raise awareness and work towards a cure for this disease. Billie didn't have to do any more to convince me to support JDRF.

Billie's outstanding efforts include talking to over 600 people at a charity ball, as a Youth Ambassador, participating in JDRF Walks to Cure Diabetes events, and the Kids in the House, and recently representing Australia at the US Children's Congress held in the White House. Since 2009, Billie has raised more than \$60,000 for JDRF. This is a remarkable feat.

JDRF's work is critical to the advancement of research and finding a cure for diabetes. I have learnt a lot more about JDRF's role since meeting Billie and joining the bi-partisan Parliamentary Diabetes Support Group (PDSG) in 2008. I look forward to the day we find a cure for diabetes.



connecting communities

Finding a cure for type 1 diabetes has motivated thousands of passionate people over four decades and will continue to do so until a solution is found.

JDRF embraces responsibility for connecting the type 1 diabetes community with each other, while also being the source for up-to-date research news.

We deliver and support a variety of services to help the type 1 diabetes community to access information and technology that can help to achieve a healthier life.

Reaching out to newly diagnosed children and adults

KIDSAC offers support and information for newly diagnosed children and their families. KIDSAC contains a special teddy bear with type 1 diabetes, a storybook, a blood glucose monitor, ketone testing strips, and an information kit for parents.

The t1d kit meets the distinct needs of newly diagnosed adults. It includes a carbohydrate counter, blood glucose meter, ketone strips and finger wipes. It also includes a copy of *Straight to the Point*, an information book produced by JDRF providing useful information for adults living with type 1 diabetes.

In 2010/11, over 2200 of these important resources were distributed free of charge through health professionals across Australia.

Thank you to Sanofi Australia New Zealand and Roche Diabetes-Care for their long term support of the KIDSAC and t1d programs.

Families helping families

The JDRF Peer Support Program is a localised one-on-one support network that connects trained volunteers who have personal experience of life with type 1 diabetes with newly diagnosed individuals or families that need support.

This year, more than 100 devoted volunteers connected with almost 1000 newly diagnosed adults and families, providing information, support and friendship during a difficult period of adjustment.

Thank you to all those who have shared their knowledge and compassion through JDRF support programs.

Sharing the hope for a cure

JDRF Advocates and Youth Ambassadors are members of the type 1 diabetes community who speak from the heart to raise awareness about the disease.

They reach out to corporate partners, policy makers, the media, fundraising organisations, schools and workplaces to increase awareness and support.

There are now around 600 JDRF Youth Ambassadors and Advocates across Australia. Thank you for your time, enthusiasm, and courage.

Connecting online communities

The JDRF monthly email newsletter and interactive online blog, 'Path to a Cure', now has more than 34,000 subscribers.

Path to a Cure delivers the latest research news as well as sharing stories about the many ways that the type 1 diabetes community connects with government, business and each other.

Members of the type 1 diabetes community exchange personal perspectives through the JDRF blog, Facebook, Twitter and LinkedIn.

Rewarding accurate media reporting

The Jelly Baby Awards recognise excellence in the reporting of type 1 diabetes. The 2011 winning articles were selected by an independent panel of judges that includes members of the type 1 diabetes community with a special interest or experience in media.

Winner (Print media) – Emma Quayle 'A dog's new life' *The Sunday Age*.

Runner up (Print media) – Nick Miller 'Blood sugar sensor could save diabetics' lives' *The Age*.

Winner (Health and clinical media) – Catherine Hanrahan 'Nature vs. Nurture Diabetes Onset' *Medical Observer*.

Runner up (Health and clinical media) – Catherine Price 'Rebooting the body' *Popular Science*.

Winner (Broadcast media) – Jacqueline Tonks 'Type 1 diabetes, disease and life' *The 7pm Project*.

JDRF would like to thank these journalists for their stories, and for the contribution they have made to raising awareness about type 1 diabetes. Thanks also go to Medtronic for their support of this program.



Kerrie McCallum

My 3 year old daughter Marley was diagnosed with type 1 diabetes this year.

The experience was intense and all-consuming but once the mayhem of diagnosis was over I was surprised at how alone I felt. No one seemed to understand how absorbing and how high maintenance life had become. Not to mention the constant fear for the future.

Someone suggested I join the JDRF Peer Support Program and from the first conversation I felt more optimistic. It was so comforting to know that others are experiencing the same challenges,

and the advice and support I received was invaluable. Marley went on a pump recently so I connected back into the network.

We still have ups and downs, but on the whole, life is becoming more manageable. A wise person told me to make type 1 diabetes your friend not your enemy and we've found that to be a positive way to live. Day-to day, I give Marley the best tools I can to empower her to live a long and healthy life, but I would still love for there to be a cure. So Marley, and our family, could live with freedom.

Updating health professionals

Diabetes-related health care professionals use JDRF to stay connected with the type 1 diabetes community and remain updated on research breakthroughs.

Clinicians and researchers who seek to grow their type 1 diabetes expertise by travelling to attend scientific symposiums and seminars are supported by JDRF with generous help from the Macquarie Group Foundation. This year, JDRF awarded 16 grants for travel to research institutions or conferences.

Enabling access to the best technology

Launched in 2008, the Type 1 Diabetes Insulin Pump Program provides Australian government-funded subsidies to help make insulin pump therapy more affordable and accessible to children under 18.

The means-tested subsidy is available to anyone who does not have private health insurance and is under 18 at the time of application. Up to 80% of the cost of the insulin pump may be covered.

An information brochure distributed through the NDSS, alongside increased hospital support in 2010/11, resulted in an increase in applications and 118 pump subsidies granted. 188 insulin pumps have now been provided to children and young people from around the country.

Over 188 insulin pumps have now been provided to children and young people from around the country.

JDRF has also established partnerships with Diabetes Australia Queensland and the Australian Diabetes Council to support families in QLD and NSW that qualify for the full 80% subsidy but struggle to make the required co-payment.

Recognising excellence in diabetes care

The JDRF Diabetes Educator of the Year Award program recognises and thanks Diabetes Educators for their exceptional contribution and dedication to the lives of people with type 1 diabetes. The program rewards the passion, dedication, time and experience that they share with the community by stewarding their patients towards happy and healthy lives.

Through the generous support of Abbott Diabetes Care, three Diabetes Educators were awarded \$1,500 to spend on resources and facilities.

The recipients of awards for 2010 were:

Barbara McRae – Gippsland Southern Health Service, Leongatha VIC

Awarded for the establishment of a rural-based DAFNE (Dose Adjustment For Normal Eating) centre.

Maggie Lasdauskas – Diabetes Tasmania, Hobart TAS

Awarded for the coordination of four educational diabetes camps targeting young adults between the ages of 18 and 30.

Deb Foscett – Insulin Pump Angels, Helensvale QLD

Awarded for the establishment of the first Gold Coast based Insulin Pump Clinic that supports pump therapy right across south-east Queensland.





funding the future

JDRF provides numerous opportunities for people to make a contribution of any kind.

Whether our supporters are wearing a bike shirt or a ball gown, jumping out of a plane or simply buying a packet of JDRF jelly babies, the focus

is always serious – raising as much money as possible for research into the cure, treatment and prevention of type 1 diabetes.

Walk to Cure Diabetes

In 2010/11, thousands of individuals, families, workmates, and friends came together in the JDRF Walk to Cure Diabetes, one of Australia's largest fundraising events.

A total of \$1.75 million was raised with 20 individual Walk events held in capital cities and rural centres around the country.

Since establishment in 1994, this event has raised over \$22 million for Australian type 1 diabetes research and provided the type 1 diabetes community with a valuable opportunity for friendship and support.

Thank you to the National Walk Leaders – Boral, Westpac Group, and Ford Motor Company.

Ride to Cure Diabetes

Ride to Cure Diabetes celebrates teamwork, friendship and a spirit of adventure. Participants challenge themselves to ride long distances whilst setting themselves significant fundraising targets. This year, 301 participants raised almost \$900,000 for diabetes research.

JDRF was proud to award the Spirit Award to Susan Hope-Blyth, and the Highest Corporate Team Fundraising Award to Boral, who raised over \$250,000 through their team fundraising.

Thank you to Motorola, Bernie Jones Cycles, event patron Stephen Hodge, Rotary and Kiwanis Clubs of the Barossa Valley and St John's Ambulance for their assistance and support.

Spin to Cure Diabetes

The Spin to Cure Diabetes was held in Sydney, Brisbane, Melbourne, Adelaide and Perth. Hundreds of participants from corporate partners around the country raced on stationary bikes and raised over \$200,000. Congratulations to our highest fundraiser, James King, who raised \$13,850 with his team the Chrystobel Cruisers.

Thank you to Goodlife Health Clubs for their support through the provision of spin bikes across the country.

Jelly Babies

JDRF's cheery Jelly Baby symbol was seen across the country in May 2011, raising much needed funds and awareness of a serious message.

Thank you to national partners Woolworths and Safeway supermarkets and Amcal, MyChemist and Chemist Warehouse pharmacies for their ongoing support of Jelly Baby Month merchandise sales. Thanks also must go to the hundreds of dedicated volunteers across Australia who donned jelly baby suits, sat in shopping centres or visited schools to help raise just under \$900,000 this year.

Special Events

JDRF and supporters are famous for their glamorous gala balls and the last year was no exception. Of particular note was the 25th Annual Susan Alberti Charitable Foundation Signature Ball to benefit JDRF. Held in Melbourne, over 500 guests celebrated the contribution of JDRF Australia President Dr Susan Alberti AO and highlighted the achievements that have been made from their generous support through the Signature Ball.

Other special events including gala balls and golf days were held around the country and raised over \$1 million for type 1 diabetes research. The first Jump to Cure Diabetes was held in South Australia and raised over \$38,000.

A special thank you goes to Frank and Sophia Jackson, Macquarie Group and the Macquarie Group Foundation for their personal efforts and financial support of Gala Balls around the country, committee members and volunteers are vital to the success of special events. Thank you to those who assisted for your important contribution.

Team Cure Diabetes

In February 2011 JDRF launched Team Cure Diabetes, a virtual team of passionate people coordinating fundraising events to support the JDRF mission to find a cure for type 1 diabetes.

Team Cure Diabetes is designed to involve supporters who wish to contribute in their own way, no matter how large or small.

In 2010/11, Team Cure Diabetes members participated in a huge range of activities including the City to Surf in Perth and Sydney, Bridge to Brisbane, 24hr World Mountain Bike Challenge, City-Bay Run Melbourne and the London Marathon.

They also organised exhibitions, kayaked the Murray River, climbed Mt Kilimanjaro, shaved heads and collected donations in lieu of gifts. Events involved included PricewaterhouseCoopers Trivia Night, Wynnum Golf Day, Medibank International Tennis and the City Beach wristband campaign.

Of particular note was the first JDRF Alpe d'Huez Global Cycle Challenge. Held in France, 28 individuals from Macquarie Group offices around the world cycled to raise over US\$370,000 globally for JDRF. JDRF thanks the nine Australian participants along with the Macquarie Group Foundation for supporting their staff in this challenging event.

This year Team Cure Diabetes contributed over \$640,000 and involved over 500 fundraisers – an exciting result for JDRF and a challenge to our community to raise even more next year!





Roy Laidlaw

Alpe d'Huez Global Cycle Challenge

When my work colleague, Matt Rady, approached me with the idea of a cycling up the Alp d'Huez for JDRF, I loved the idea and signed up even though I had not ridden seriously for almost 15 years. Word spread and before we knew it, 28 riders from Australia, Canada, England, India and the US had signed up. With help from local JDRF offices, and the promise of matching funds from the Macquarie Group Foundation, we raised almost US\$400,000 for JDRF.

The conditions on the final day of our 3 day challenge were brutal with freezing cold winds, torrential rain and

even thunder and lightning. Our final climb was up the legendary 21 hairpin turns to the ski resort of Alpe d'Huez – more commonly known as one of the deciding days in the Tour de France. It was a long slow grind and we all needed a fair bit of mind over matter - many of us focused on the mantra "it's for the kids, it's for the kids, its for the kids".

It was all worth it when we finished. After celebrating with a hot jacuzzi to warm up and a few drinks, we were all proud to have completed the challenge whilst raising money for a great cause.

Partnering with Business

JDRF shares the hope for a cure for type 1 diabetes with some of Australia's most successful companies, who offer expertise and financial support as well as joining the type 1 diabetes community at fundraising events.

Boral Limited

Boral has participated in nearly every JDRF fundraising activity over the last decade to raise in excess of \$2.55 million for type 1 diabetes research. In many cases, this fundraising involves family members, customers and suppliers. In recognition of their achievement, Boral was awarded the 2010 Freedom Award for the greatest annual contribution to JDRF fundraising programs by a corporate supporter.

City Beach

For the last six years, one of Australia's largest surfing chains City Beach has supported JDRF by selling exclusive fundraising wristbands. Their contribution to Australian research has reached almost \$900,000. Thank you City Beach and the Ierna family for your enduring support.

Woolworths

Each year, Woolworths and Safeway customers across Australia join in the mission to find a cure for type 1 diabetes by supporting Jelly Baby Month. Sales of Jelly Baby Month merchandise have nearly doubled since the inception of this partnership in 2003.

Macquarie Group and the Macquarie Group Foundation

With a partnership spanning almost ten years, Macquarie Group is a committed participant in JDRF fundraising, strategic development and corporate governance. Contributions from Macquarie Group teams, and matching donations and support from the Macquarie Group Foundation, total just under \$2 million and offices in the US, UK and Canada are also becoming involved with local JDRF events.

Ford Motor Company

The Ford Motor Company is a global sponsor for the Walk to Cure Diabetes. In Australia, Ford staff have enthusiastically participated in the Victorian Walk event for over ten years, coordinating a number of innovative events throughout the year that have contributed over \$230,000 for local JDRF funded research.

Pro Bono and In-Kind Support

The generosity of volunteers and supporters who donate their time allows JDRF to keep our costs as low as possible.

This year a number of companies and individuals from around Australia supported JDRF by providing services or equipment free of charge.

Organisational support

JDRF is a founding partner of the Organisational Mentoring Program run by Westpac's Sustainability and Community Involvement Team. This diverse support helps JDRF to deliver on the mission to find a cure for type 1 diabetes, while also building capacity for the next generation of JDRF research investment.

Network and computer support

JDRF's nine year partnership with IBM Global Services has provided exceptional technology support on a pro bono basis, helping JDRF to focus resources in finding a cure for type 1 diabetes. In 2011, DNS IT services also joined the team, providing additional pro bono expertise for day-to-day technical support and longer term IT planning.

Infrastructure support

Macquarie Group partnered with the Commonwealth Bank to finance and coordinate the renovation of the largest JDRF office in Sydney. Our sincere thanks also go to those who volunteered their time and expertise from LendLease, Paragon, Newks Investments and Movers & Shakers. By supporting this substantial project, these organisations enabled JDRF to direct even more money towards our mission.

Volunteers Sharing the Hope for a Cure

JDRF was established by volunteers, a group of parents who would not accept that there was no cure for type 1 diabetes.

Today, a talented, diverse and dedicated group of people partner with JDRF in every aspect of our business. Volunteers are the power that drive most of our fundraising activities, whether generating the ideas, staffing an event or crunching numbers on a computer.

JDRF Advocates, Ambassadors and their families share their time and life stories to raise awareness of type 1 diabetes amongst Australian decision makers.

JDRF also relies upon the donated time, passion and expertise of a number of business leaders to ensure we stay on top of the game.

We sincerely thank all of our volunteers for making so many things possible.

The Generosity of Individuals

JDRF acknowledges that there are a number of ways in which people can support our mission through their time, talent or treasures. Life can become busy and many supporters don't have the time, or the ability, to continue to coordinate fundraising events. For these people, a number of alternative ways to make a contribution are outlined below.

Research Investors

Research Investors are a very special group of people who contribute \$10,000 or more to JDRF Australia in a financial year.

Million Dollar Club

This Club aims to bring together 1,000 like-minded individuals to donate \$1,000 each year to JDRF, making a significant impact on the Australian diabetes research landscape by investing \$1 million annually.

Regular giving

Supporters can choose to make regular annual or monthly gifts towards JDRF research. By pledging a set regular amount, JDRF can effectively plan what funds are available to support future research endeavours. It doesn't matter if you contribute \$10 or \$10,000, each dollar makes a difference.

Bequests and the Danielle Alberti Legacy Society

In 2001, Danielle Alberti, a talented young artist and the only child of JDRF Australia President Dr Susan Alberti AO, died tragically of complications from type 1 diabetes. The Danielle Alberti Legacy Society recognises supporters who have included a gift to JDRF in their will and remembers people like Danielle. Leaving a bequest to JDRF in your will ensures a lasting legacy of investment in type 1 diabetes research in Australia.

There are many other ways to support JDRF financially, including making a pledge or naming JDRF as a beneficiary of life insurance or superannuation policies. Further information about joining the search for a type 1 diabetes cure through any of these avenues can be obtained from our Donor Relations Manager on (02) 9020 6100.



Kristen Mason


My daughter Taylor developed type 1 diabetes when she was only 10 months old. We turned to JDRF for information and support during that incredibly stressful time and as Taylor has grown, so has our relationship with JDRF.

I'm a working mum and I don't always have lot of time or money to spare but I try to support JDRF whenever I can. Over the last nine years, Taylor and

I have walked to cure diabetes every year, organised gala balls, met with our local politicians and acted as JDRF Ambassadors at every opportunity. I am honoured to also be a member of the JDRF Australia Board of Directors.

Recently, I decided to leave a bequest to JDRF in my Will to make sure a cure is found, even if I'm not alive to see it. I want Taylor to know what life is like without type 1 diabetes.

linking into expertise



JDRF Corporate Governance

The Juvenile Diabetes Research Foundation and its Board are committed to achieving and demonstrating the highest standards of corporate governance, with a framework based on best practice recommendations released by the Australian Securities Exchange Corporate Governance Council.

A full description of JDRF corporate governance practices is available at www.jdrf.org.au. All these practices, unless otherwise stated, were in place for the entire reporting period.

Financial Management

JDRF is a registered charitable organisation. Its principal activities are to raise funds to support research to find a cure for and prevent type 1 diabetes, to raise awareness of the seriousness of diabetes and to offer practical support to people with diabetes and their families. JDRF financial activities are geared towards achieving this goal with minimal expenditure on company administration and minimal financial risk.

A Finance and Audit Committee is regularly convened to provide oversight and advice on the financial and compliance activities of the organisation. It's responsible for working with JDRF to develop and track budgets, monitor forecasts, and review management and statutory accounts. Comprising the following Board and independent members, the committee includes appropriate financial expertise and understanding of the sector.

- Chair - Trevor Allen (Treasurer and Director of JDRF)
- Stephen Higgs (Chair of JDRF)
- Peter Wilson (Vice-Chair of JDRF)
- Independent member - Allison McMartin (ANZ Institutional Banking)
- Independent member - Boris Musa (Macquarie Group)
- Independent member - Peter Whyntie (Novus Capital)

JDRF voluntarily appoints PricewaterhouseCoopers as an external auditor.

Risk assessment and management

The Board is responsible for ensuring adequate policies in relation to risk management, compliance and internal control systems. Company policies have been designed to ensure risks are identified, assessed, effectively and efficiently managed and monitored to enable achievement of the organisation's objectives.

Environment, health and safety

JDRF recognises the importance of environmental and occupational health and safety (OH&S) issues and is committed to the highest levels of performance. Areas of OH&S risk are reviewed and addressed by a Risk Management Committee with input from across the organisation. JDRF has undertaken an environmental audit to determine ways to minimise its impact on the environment including recycling and energy conservation programs.

Code of Conduct

JDRF has a formal Statement of Values and Code of Conduct which has been fully endorsed by the Board and applies to all directors, employees, volunteers and event participants. It reflects the highest standards of behaviour and professionalism and the practices necessary to maintain confidence in the organisation's integrity. A copy of the Code of Conduct is available on the JDRF website.

Board of Directors

The JDRF Australia Board of Directors operates in accordance with the broad principles set out in its constitution as adopted by the company on 8 April 2000. Details of the officers and members of the Board, their experience, expertise, qualifications and term of office are presented below.

Directors Qualifications and Special Responsibilities	Experience
President of the Board & International Patron Dr Susan Alberti , AO HonLLD Member of JDRFI Board of Chancellors Member of Major Donor Committee JDRF International Retired Member of Board of Directors JDRFI Retired Member of JDRFI International Development Committee	Managing Director, Dansu Group. Founding member of the National Association of Women in Construction in Australia. Associate fellow, CEO Institute. Chair, St. Vincent's Institute Foundation. Chair, Susan Alberti Charitable Foundation. Director, Western Bulldogs Football Club. Director, St Vincent's Institute. Co-Chair, Western Bulldogs Forever Foundation. Director, Click Foundation (Epilepsy). Director, Victorian University Foundation Board. Director, Gold Age Pty Ltd. Mother of a daughter with type 1 diabetes
Chairman Stephen Higgs , BEc Member, Finance Committee Member, Ad Hoc Lay Review Panel after 3 years on the full committee Member, NSW Corporate Committee	Director, Peet and Company Ltd, Diabetes Vaccine Development Centre. Chairman, Glycemic Index Ltd. Past Chairman, Orlando Wines. Past Director, Primary Health Care, Austoft Pty, Jasco Pty Ltd, NPL Ltd, Leigh Mardon Pty Ltd, Rural Press Ltd and UBS Warburg, IPAC Securities Ltd and So Natural Foods Ltd. Father of a son with type 1 diabetes.
Vice-Chair Rebecca Davies , LLB (Hons), BEc, FAICD Member of the Board of JDRF International Chair of the JDRFI International Development Committee Member of the Executive Board for the Islet Transplant Program Member of the JDRFI Research Committee	Solicitor and Company Director. Former partner and board member of a major national law firm. Former Chair of MLC Nominees, trustee for NAB/MLC public offer superannuation funds. Member of the Private Health Insurance Administration Council and former Chair of its Audit and Compliance Committee. Director of LCM Health Care Limited and its subsidiaries and member of its Audit and Risk Committee. Director of Westpac/BT superannuation and financial services subsidiaries and Chair of its Investment Committee. Mother of a daughter with type 1 diabetes.
Vice-Chair Peter Wilson , Dip. Chem. BEc Member of the Finance & Audit Committee for JDRF Australia Member and former Chair of JDRFI Finance Committee Member and former Chair of the JDRFI International Development Committee Member of the Victorian Corporate Committee Member of JDRFI Board of Chancellors Retired member of JDRFI Board of Directors Former President of Long Island, New York, Chapter of JDRF	Managing Director PAGA Consulting Pty. Ltd. Former Managing Director and Chief Executive Officer Spotless Group Limited. Former Director of Spotless. Director of Taylors Group Limited (a New Zealand Company). Director Stanhope Eco Trade Pty Ltd. Father of a daughter with type 1 diabetes.

Directors Qualifications and Special Responsibilities

Experience

Treasurer Trevor Allen , BCom (Hons), CA, FF, MAICD Chair of the Finance & Audit Committee	National Head of Mergers and Acquisitions, KPMG. Executive Director, KPMG Corporate Finance (Aust) Pty Ltd. Partner, KPMG. Member of the Market Policy Committee of FINSIA. Past director UBS Warburg. Relative with type 1 diabetes.
Robert Antulov , BE, MBA, MIEAust, MAICD	Partner at Hall Capital Strategies Pty Ltd. Director Medianext Pty Ltd. Former Director of Strategy, Fairfax Media Ltd. Father of a son with type 1 diabetes.
Stuart Green , BA (Hons), MBA, FCA, ACMT (Appointed 7 October 2010)	Executive Director, Head of Corporate Communications and Investor Relations, Macquarie Group Limited.
Frank Jackson Life-member, JDRF Founding President, JDRF WA Chapter Founding committee member, Walk to Cure Diabetes – WA	Managing Director, Frank Jackson Holdings Pty Ltd. Chairman of The Jackson Family Foundation. Former Director of Broadwater Resort Management. Former Council Member of The Owners of Broadwater Grand Mercure Busselton. Former Managing Director, Broadwater Beach Bar and Restaurant, Busselton. Father of a daughter with type 1 diabetes.
Ross Kennan , FIEA CP Eng. FAICD C.Chem MRACI Member of the Compliance Committee	Chairman, Neptune Marine Services Ltd. Director, Dadanco P/L and Dadanco Inc. (USA). Former Global SBU Vice-President of Honeywell Inc.
Natasha Mandie , B Comm (Hons), LLB (Hons), GAICD	Director, Corporate Advisory Solutions, Credit Suisse. Has type 1 diabetes.
Kristen Mason , MBA Chair of the NSW Ball Committee	Manager, Travel Partner Networks, JAPA, American Express. Former Director of Foundation - Kambala. Mother of daughter with type 1 diabetes.
Helen McCombie Member of the NSW Corporate Committee	Partner, Citadel PR, a corporate communications consultancy. Former reporter on Channel 9's Business Sunday program.
Timothy Morphy , BA, LLB, MBA	Managing Director of Healthways Australia Pty Ltd Former General Manager Marketing, I-Med Network Limited National Head of Marketing, Medibank Private Limited.
Michael White , BA, MBA Member JDRFI Board of Chancellors Chair of JDRFI Strategic Alliance Committee Past Member JDRFI Executive Committee Past Chair of Research JDRFI Past Chair of Research Development Committee JDRFI Past President Desert Southwest Chapter JDRFI	President and Owner of RBW Companies, Inc. (USA). Father of a son with type 1 diabetes.
Mike Wilson , BSc, BEc (Hons), GAICD (appointed 25 November 2010) Company Secretary	Chief Executive Officer of the Juvenile Diabetes Research Foundation since November 2004. Director, Glycemic Index Foundation. Alternate Director, Diabetes Vaccine Development Centre.

JDRF Advisory Board

The Advisory Board meets to provide JDRF with guidance and advice from Australia's most knowledgeable business people. JDRF would like to thank the following members for their support and involvement throughout the year.

Co-Chairs

Richard Goyder	CEO and Managing Director, Wesfarmers
Ralph Norris	CEO and Managing Director, Commonwealth Bank

Members

Rob Antulov*	Director, Hall Capital Strategies
Chris Corrigan	Director, POTA Holdings Pty Ltd
Rebecca Davies*	Director, Westpac/BT Superannuation and Financial Services
Rick Dennis	Managing Partner, Oceania Operations & Finance, Ernst & Young
John Doumani	Managing Director, Fonterra
Matthew Grounds	Global Head of Investment Banking, UBS
Steve Higgs*	Chairman, JDRF
Rod Pearse	Former CEO and Managing Director, Boral
Peter Mason AM	Chairman, AMP
Helen McCombie*	Director, Citadel PR
Howard McDonald	Chairman, Myer
Nicholas Moore	Managing Director and CEO, Macquarie Group
Chris Mort	Chairman and CEO, McCann Worldgroup
Andy Penn	Former Group Chief Executive, AXA Asia Pacific Holdings
Bill Wavish	Former Executive Chairman, Myer
Peter Wilson*	Former Managing Director, Spotless Group
Mike Wilson*	CEO, JDRF

* Also a director of JDRF

Advisory Panels

JDRF Advisory Panels are unique in their structure, incorporating leading scientific input and a focus on the human relevance of research.

Professional Advisory Panel

The JDRF Professional Advisory Panel is composed of leading scientists from around Australia. Panel members help ensure that JDRF investment in research is directed towards high quality projects with the greatest scientific potential.

Chair

Prof Philip O'Connell	Westmead Millennium Institute
-----------------------	-------------------------------

Members

Prof Trevor Biden	Garvan Institute of Medical Research
Dr Tom Brodnicki	St Vincent's Institute of Medical Research
Dr Stuart Mannering	St Vincent's Institute of Medical Research
Prof Bernie Tuch	CSIRO
Prof Timothy Jones	Princess Margaret Hospital

Lay Review Panel

JDRF's Lay Review Panel is composed of people who have a personal connection to type 1 diabetes to ensure that JDRF research is directed towards projects with the greatest potential to transform the lives of those with type 1 diabetes.

Chair

Rachel Reyna	Has type 1 diabetes (resigned Mar 2011)
Christine Garberg	Parent of child with type 1 diabetes (from Mar 2011)

Members

Michelle Baker	Parent of child with type 1 diabetes (resigned Oct 2010)
Tony Blanch	Has type 1 diabetes
Jo Crosby	Parent of child with type 1 diabetes
Dr Gerard Cudmore	Relative with type 1 diabetes
Rebecca Davies	Parent of child with type 1 diabetes
Ed Davis	Parent of child with type 1 diabetes
Marilyn Harrington	Parent of child with type 1 diabetes
Stephen Higgs	Parent of child with type 1 diabetes
Dianne Kerr	Parent of child with type 1 diabetes
Rhonda Harrup	Parent of child with type 1 diabetes
Natasha Mandie	Has type 1 diabetes

Allied Health and Nursing Professional Advisory Panel

Allied health professionals are part of the diabetes management team and include nurses, dietitians, psychologists, social workers, and podiatrists.

Chair

Dr Jane Overland	Royal Prince Alfred Hospital
------------------	------------------------------

Members

Ms Deb Foote	Royal Prince Alfred Hospital
Ms Erica Wright	Diabetes Service ACT Community Care

JDRF Australia Leadership Team

Photographs:
Mike Wilson,
James Clampett



Leadership Team

CEO	Mike Wilson, BSc, BEc (Hons) GAICD
COO	William Bonney, MMgt, FAICD (Until Jun 11)
Head of Development	James Clampett, BEc
Head of Marketing	Carl Ireland, BBus (Mktg), Grad. Dip. (Mktg)
Head of Government	Margaret Ryan, BEc(Hons), DipEd, DipMultEd (until Sep 10) Tanya Stoianoff, B Agr.Ec, MPS
Head of Research Development	Dorota Pawlak, MSc, PhD



Photographs:
Carl Ireland,
Tanya Stoianoff,
Dorota Pawlak

JDRF Financial Report

The following summarised financial report presents a true and fair view, in all material respects, of the financial condition and operational results of the company and are in accordance with relevant accounting standards. A full audited financial report for 2010/11 is available on the JDRF website www.jdrf.org.au.

Statement of Comprehensive Income for year ended 30 June 2011

	Year to 30 June 2011	Year to 30 June 2010
	\$	\$
Revenue from continuing operations – fundraising & other income	9,121,409	8,734,984
Revenue from continuing operations – government grants	840,600	4,639,868
Total revenue from continuing operations	9,962,009	13,374,852
Revenue from shares	–	7,774
Employee benefits expenses	(2,389,558)	(2,282,345)
Fundraising campaign expenses	(653,145)	(724,210)
Communications & technology expenses*	(176,764)	(126,791)
Advertising, promotion and printing expenses	(208,746)	(143,992)
Other expenses	(1,335,546)	(1,176,857)
Surplus from continuing operations	5,198,250	8,928,431
Research grants and travel awards	(5,082,901)	(8,367,742)
Education and support	(148,177)	(569,651)
Profit/(Loss) on fixed asset disposal	–	–
Surplus / (deficit) before tax	(32,828)	(8,962)
Income tax expense	–	–
Surplus / (deficit) from continuing operations	(32,828)	(8,962)
Other comprehensive income		
Other comprehensive income / (expense) for the period, net of tax	–	–
Total comprehensive income / (expense) for the period	(32,828)	(8,962)

*2011 - \$27,090 in-kind technology support (2010 - \$24,500)

Statement of Financial Position as at 30 June 2011

Assets	As at 30 June 2011 \$	As at 30 June 2010 \$
Current assets		
Cash and cash equivalents	9,136,882	11,641,078
Trade and other receivables	779,745	693,870
Inventories	194,152	109,725
Total current assets	10,110,779	12,444,673
Non-current assets		
Plant and equipment	180,193	35,369
Intangibles	6,302	27,727
Total non-current assets	186,495	63,096
Total assets	10,297,274	12,507,769
Liabilities		
Current liabilities		
Trade and other payables	5,979,870	6,851,330
Research grants payable	–	1,325,869
Provision for Long Service Leave	25,635	18,393
Total current liabilities	6,005,505	8,195,592
Non-current liabilities		
Provision for Long Service Leave	65,120	52,700
Total non-current liabilities	65,120	52,700
Total liabilities	6,070,625	8,248,292
Net assets	4,226,649	4,259,477
Equity		
Retained surplus	4,226,649	4,259,477
Total equity	4,226,649	4,259,477

Statement of Cash Flows for year ended 30 June 2011

	Year to 30 June 2011	Year to 30 June 2010
	\$	\$
Cash flows from operating activities		
Fundraising income	8,299,187	8,515,534
Government grants	610,000	9,981,000
Interest received	379,571	176,044
Payments for operating activities	(5,667,028)	(4,105,887)
Grants and travel awards paid	(6,088,344)	(15,544,736)
Net cash inflow from operating activities	(2,466,614)	(978,045)
Cash flows from investing activities		
Payments for plant, equipment & software	(37,582)	(47,661)
Net cash (outflow) from investing activities	(37,582)	(47,661)
Net increase in cash and cash equivalents	(2,504,196)	(1,025,706)
Cash and cash equivalents at the beginning of the financial year	11,641,078	12,666,784
Cash and cash equivalents at the end of the financial year	9,136,882	11,641,078

Statement of Changes in Equity for year ended 30 June 2011

	Year to 30 June 2011	Year to 30 June 2010
	\$	\$
Total equity at the beginning of the financial year	4,259,477	4,268,439
Net surplus/(deficit) attributable to members of the company	(32,828)	(8,962)
Total equity at the end of the financial year	4,226,649	4,259,477

Directory of JDRF Offices

New South Wales

Level 4, 80 Chandos Street
St Leonards NSW 2065
Tel: 02 9020 6100
Fax: 02 9966 0172
nsw@jdrf.org.au

Queensland

Level 5, Wickham House
155 - 157 Wickham Terrace
Spring Hill QLD 4000
Tel: 07 3831 0544
Fax: 07 3236 9634
qld@jdrf.org.au

Victoria

Suite 1, Level 1,
222 Kings Way
South Melbourne VIC 3205
Tel: 03 9696 3866
Fax: 03 9696 7659
vic@jdrf.org.au

Australian Capital Territory

16 Thesiger Court
Deakin ACT 2600
Tel: 02 6249 8555
Fax: 02 6162 0390
act@jdrf.org.au

South Australia

458 Fullarton Road
Myrtle Bank SA 5064
Tel: 08 8338 3677
Fax: 08 8338 6017
sa@jdrf.org.au

Western Australia

Unit 3, 181 Main Street
Osborne Park WA 6017
Tel: 08 9207 1278
Fax: 08 9207 1298
wa@jdrf.org.au

